AbbVie, Zumilokibart, APG777, Atopic Dermatitis, APEX Part B, Phase 2 Clinical Trial, Phase 3 Development, IL-13, Monoclonal Antibody

North Chicago, Illinois, U.S., September 30, 2026 AbbVie announced positive Phase 2 results for zumilokibart (APG777) in adults with...